Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Molecular and Clinical Features of FLT3 Juxtamembrane Domain Point Mutations (muts) in Acute Myeloid Leukemia (AML)

Nadeen Anabtawi, Jessica Kohlschmidt, Daelynn Buelow, Shelley Orwick, Kennedy Coleman, Krzysztof Mrózek, Jonathan E. Kolitz, Bayard L. Powell, William G. Blum, Maria R. Baer, John C. Byrd, Wendy Stock, Geoffrey L. Uy, Ann-Kathrin Eisfeld, Sharyn Baker, James S. Blachly

Blood (2022) 140 (Supplement 1): 6244–6246.

https://doi.org/10.1182/blood-2022-171222

Published: 2022

Journal Articles

Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])

Blood (2022) 140 (Supplement 1): 936–939.

https://doi.org/10.1182/blood-2022-165395

Published: 2022

Journal Articles

Identification of PTPN11 mutations As Early Events in the Development of Acute Myeloid Leukemia

Sydney Fobare, Shelley Orwick, Jessica Kohlschmidt, Tom Sesterhenn, Krzysztof Mrózek, Ben Wronowski, Megan Johnstone, Andrew J. Carroll, Richard M. Stone, Eunice S. Wang, Jonathan E. Kolitz, Bayard L. Powell, John P Perentesis, Ann-Kathrin Eisfeld, Erin Hertlein, John C. Byrd

Blood (2022) 140 (Supplement 1): 743–744.

https://doi.org/10.1182/blood-2022-160323

Published: 2022

Journal Articles

Regularized Mixture Cure Models Identify a Gene Signature That Improves Risk Stratification within the Favorable-Risk Group in 2017 European Leukemianet (ELN) Classification of Acute Myeloid Leukemia (Alliance 152010)

Kellie J. Archer, Han Fu, Krzysztof Mrózek, Deedra Nicolet, Jessica Kohlschmidt, Alice S. Mims, Geoffrey L. Uy, Wendy Stock, John C. Byrd, Ann-Kathrin Eisfeld

Blood (2022) 140 (Supplement 1): 1913–1914.

https://doi.org/10.1182/blood-2022-166477

Published: 2022

Journal Articles

Characterization of Survival Outcomes and Clinical and Molecular Modulators in Adult Patients with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated with Hidac Consolidation: An Alliance Legacy Study

Jonathan Hyak, Deedra Nicolet, Jessica Kohlschmidt, Kellie J. Archer, James S. Blachly, Karilyn T. Larkin, Bayard L. Powell, Jonathan E. Kolitz, Maria R. Baer, William G. Blum, Geoffrey L. Uy, Wendy Stock, Richard M. Stone, John C. Byrd, Krzysztof Mrózek, Ann-Kathrin Eisfeld, Alice S. Mims

Blood (2022) 140 (Supplement 1): 1284–1285.

https://doi.org/10.1182/blood-2022-167210

Published: 2022

Journal Articles

Molecular Landscape in Acute Myeloid Leukemia (AML) Patients (pts) from Mexico As an Initial Study to Identify Healthcare Disparities in Hispanic Populations: Alliance for Clinical Trials in Oncology [Alliance]

Nuria Mencia Trinchant, Jessica Kohlschmidt, Alexandra Gomez-Arteaga, John C. Byrd, Wendy Stock, Krzysztof Mrózek, Andrew J. Carroll, Richard M. Stone, Eileen Pacheco, Adolfo Martinez Tovar, Irma Olarte Carrillo, Anel Garcia Laguna, Christian Ramos Peñafiel, Duane C Hassane, Ann-Kathrin Eisfeld, Monica L. Guzman

Blood (2022) 140 (Supplement 1): 11009–11010.

https://doi.org/10.1182/blood-2022-170326

Published: 2022

Journal Articles

Targeting the WT1 mut -M ir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir -193a-3p Mimic in Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 6224–6225.

https://doi.org/10.1182/blood-2022-157833

Published: 2022

Journal Articles

Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study

Krzysztof Mrózek, Jessica Kohlschmidt, James S. Blachly, Deedra Nicolet, Andrew J. Carroll, Kellie J. Archer, Alice S. Mims, Karilyn T. Larkin, Shelley Orwick, Christopher C. Oakes, Jonathan E. Kolitz, Bayard L. Powell, William G. Blum, Guido Marcucci, Maria R. Baer, Geoffrey L. Uy, Wendy Stock, John C. Byrd, Ann-Kathrin Eisfeld

Blood (2022) 140 (Supplement 1): 6318–6320.

https://doi.org/10.1182/blood-2022-167352

Published: 2022

Journal Articles

Adverse Outcomes in Acute Myeloid Leukemia Are Associated with Tumor Cell-Mediated Immunosuppression

Blood (2021) 138 (Supplement 1): 800.

https://doi.org/10.1182/blood-2021-148645

Published: 2021

Journal Articles

Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes

Blood (2021) 138 (Supplement 1): 685.

https://doi.org/10.1182/blood-2021-153015

Published: 2021

Journal Articles

Social Deprivation Independently Predicts Survival in Younger Patients with Acute Myeloid Leukemia (Alliance)

Melanie T Rebechi, Jessica Kohlschmidt, Krzysztof Mrózek, Deedra Nicolet, Alice S. Mims, James S. Blachly, Shelley Orwick, William Blum, Bayard L. Powell, Geoffrey L. Uy, Richard M. Stone, John C. Byrd, Electra D. Paskett, Jesse Plascak, Ann-Kathrin Eisfeld

Blood (2021) 138 (Supplement 1): 1983.

https://doi.org/10.1182/blood-2021-149647

Published: 2021

Journal Articles

White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance)

Michael P. Ozga, Deedra Nicolet, Krzysztof Mrózek, Christopher J. Walker, James S. Blachly, Jessica Kohlschmidt, Shelley Orwick, Andrew J Carroll, Richard A. Larson, Jonathan E Kolitz, Bayard L. Powell, Richard M. Stone, John C. Byrd, Ann-Kathrin Eisfeld, Alice S. Mims

Blood (2021) 138 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2021-151610

Published: 2021

Journal Articles

Epigenetic Phenocopying Expands Molecular Risk Assessment in Acute Myeloid Leukemia (Alliance)

Blood (2021) 138 (Supplement 1): 803.

https://doi.org/10.1182/blood-2021-147652

Published: 2021

Journal Articles

Race-Ethnic Enrollment Disparities over 15 Years of Alliance/CALGB Acute Myeloid Leukemia Clinical Trials, Biobanks, and Correlative Science Protocols

Andrew Hantel, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, Wendy Stock, Sawyer Jacobson, Sumithra J Mandrekar, Richard M. Stone, Daniel J. DeAngelo, John C. Byrd, Gregory A. Abel

Blood (2021) 138 (Supplement 1): 111.

https://doi.org/10.1182/blood-2021-146607

Published: 2021

Journal Articles

High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance)

Blood (2021) 138 (Supplement 1): 221.

https://doi.org/10.1182/blood-2021-151072

Published: 2021

Journal Articles

Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)

Blood (2021) 138 (Supplement 1): 226.

https://doi.org/10.1182/blood-2021-152838

Published: 2021

Journal Articles

Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance)

Sydney Fobare, Jessica Kohlschmidt, PhD, Hatice Gulcin Ozer, PhD, Krzysztof Mrózek, MDPhD, Deedra Nicolet, MS, Alice S. Mims, MD, Ramiro Garzon, MD, James S. Blachly, MD, Shelley Orwick, BS, Andrew J Carroll, PhD, Richard M. Stone, MD, Eunice S. Wang, MD, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, Christopher C. Oakes, PhD, Ann-Kathrin Eisfeld, MD, Erin Hertlein, PhD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-135887

Published: 2020

Journal Articles

Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy

Marius Bill, MD PhD, Jessica Kohlschmidt, PhD, Krzysztof Mrózek, MDPhD, Deedra Nicolet, MS, Christopher J. Walker, PhD, Dimitrios Papaioannou, MD, James S. Blachly, MD, Shelley Orwick, BS, Eunice S. Wang, MD, Jonathan E. Kolitz, MD, Bayard L. Powell, MD, Andrew J Carroll, PhD, Ramiro Garzon, MD, Richard M. Stone, MD, John C. Byrd, MD, Clara D. Bloomfield, MD, Ann-Kathrin Eisfeld, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-141663

Published: 2020

Journal Articles

Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-140999

Published: 2020

Journal Articles

Meta-Analysis of Genome-Wide Association Studies of Acute Myeloid Leukemia (AML) Patients Identifies Variants Associated with Risk of 11q23/ KMT2A -Translocated and Core-Binding Factor (CBF) AML and Suggests a Role for Transcription Elongation in Leukemogenesis

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-141653

Published: 2020

NARROW

Molecular and Clinical Features of FLT3 Juxtamembrane Domain Point Mutations (muts) in Acute Myeloid Leukemia (AML)

Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])

Identification of PTPN11 mutations As Early Events in the Development of Acute Myeloid Leukemia

Regularized Mixture Cure Models Identify a Gene Signature That Improves Risk Stratification within the Favorable-Risk Group in 2017 European Leukemianet (ELN) Classification of Acute Myeloid Leukemia (Alliance 152010)

Characterization of Survival Outcomes and Clinical and Molecular Modulators in Adult Patients with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated with Hidac Consolidation: An Alliance Legacy Study

Molecular Landscape in Acute Myeloid Leukemia (AML) Patients (pts) from Mexico As an Initial Study to Identify Healthcare Disparities in Hispanic Populations: Alliance for Clinical Trials in Oncology [Alliance]

Targeting the WT1 mut -M ir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir -193a-3p Mimic in Acute Myeloid Leukemia

Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study

Adverse Outcomes in Acute Myeloid Leukemia Are Associated with Tumor Cell-Mediated Immunosuppression

Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes

Social Deprivation Independently Predicts Survival in Younger Patients with Acute Myeloid Leukemia (Alliance)

White Blood Cell Count (WBC) Levels Are Associated with Molecular Profiles and Are Independent Outcome Predictors in Acute Myeloid Leukemia (AML) Patients (Pts) (Alliance)

Epigenetic Phenocopying Expands Molecular Risk Assessment in Acute Myeloid Leukemia (Alliance)

Race-Ethnic Enrollment Disparities over 15 Years of Alliance/CALGB Acute Myeloid Leukemia Clinical Trials, Biobanks, and Correlative Science Protocols

High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance)

Comparative Outcomes and Molecular Response Predictors of IDH1/2-Mutated Adult Acute Myeloid Leukemia (AML) Patients (Pts) after Frontline Treatment with Intensive Induction Chemotherapy (IC), Targeted Inhibitors, or Hypomethylating Agents (HMA) (Alliance)

Clinical and Prognostic Implications of PTPN11 Mutations in Acute Myeloid Leukemia (Alliance)

Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy

Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance)

Meta-Analysis of Genome-Wide Association Studies of Acute Myeloid Leukemia (AML) Patients Identifies Variants Associated with Risk of 11q23/ KMT2A -Translocated and Core-Binding Factor (CBF) AML and Suggests a Role for Transcription Elongation in Leukemogenesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only